Heinrich Dreismann Sells 6,000 Shares of Myriad Genetics, Inc. (MYGN) Stock
Myriad Genetics, Inc. (NASDAQ:MYGN) Director Heinrich Dreismann sold 6,000 shares of the company’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $33.50, for a total transaction of $201,000.00. Following the transaction, the director now owns 33,743 shares of the company’s stock, valued at approximately $1,130,390.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) traded down $1.26 during midday trading on Tuesday, reaching $32.48. 1,152,900 shares of the company traded hands, compared to its average volume of 1,183,174. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $37.30. The stock has a market cap of $2,336.18, a PE ratio of 30.95, a PEG ratio of 2.14 and a beta of 0.25. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.06 and a current ratio of 2.34.
Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.05. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The company had revenue of $190.20 million during the quarter, compared to analysts’ expectations of $183.52 million. During the same quarter in the prior year, the company earned $0.23 EPS. Myriad Genetics’s revenue was up 7.2% compared to the same quarter last year. research analysts anticipate that Myriad Genetics, Inc. will post 1.05 earnings per share for the current fiscal year.
MYGN has been the subject of several research analyst reports. ValuEngine upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Friday, November 10th. Deutsche Bank upped their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Wednesday, November 8th. Cowen restated a “hold” rating and set a $25.00 price target on shares of Myriad Genetics in a research report on Sunday, September 17th. Leerink Swann restated a “market perform” rating and set a $31.00 price target on shares of Myriad Genetics in a research report on Monday, October 2nd. Finally, Stephens restated an “overweight” rating and set a $40.00 price target (up previously from $36.00) on shares of Myriad Genetics in a research report on Friday, September 22nd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Myriad Genetics has a consensus rating of “Hold” and a consensus price target of $28.10.
COPYRIGHT VIOLATION NOTICE: “Heinrich Dreismann Sells 6,000 Shares of Myriad Genetics, Inc. (MYGN) Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/12/12/heinrich-dreismann-sells-6000-shares-of-myriad-genetics-inc-mygn-stock.html.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Stock Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related stocks with our FREE daily email newsletter.